Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) Operating Margin (2016 - 2025)

ImmunityBio (IBRX) has disclosed Operating Margin for 12 consecutive years, with 168.95% as the latest value for Q4 2025.

  • On a quarterly basis, Operating Margin rose 75001.0% to 168.95% in Q4 2025 year-over-year; TTM through Dec 2025 was 226.0%, a 210823.0% increase, with the full-year FY2025 number at 226.0%, up 210823.0% from a year prior.
  • Operating Margin was 168.95% for Q4 2025 at ImmunityBio, up from 173.51% in the prior quarter.
  • In the past five years, Operating Margin ranged from a high of 168.95% in Q4 2025 to a low of 685514.29% in Q1 2022.
  • A 5-year average of 99098.61% and a median of 46212.69% in 2023 define the central range for Operating Margin.
  • Peak YoY movement for Operating Margin: soared 199735900bps in 2021, then plummeted -62345385bps in 2022.
  • ImmunityBio's Operating Margin stood at 20326.67% in 2021, then plummeted by -472bps to 116301.37% in 2022, then skyrocketed by 47bps to 61430.94% in 2023, then soared by 99bps to 918.96% in 2024, then skyrocketed by 82bps to 168.95% in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Operating Margin are 168.95% (Q4 2025), 173.51% (Q3 2025), and 269.76% (Q2 2025).